Recruiting
A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Ninetedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants - IM027-1026
Actualizado: 29 octubre, 2024 | ClinicalTrials.gov
Fase
Sexo(s)
Intervalo de edad
Lugar(es)
Recruiting
Inclusion Criteria: - Participants must be healthy males and females (INOCBP) - Participant must have Body mass index (BMI) of 18.0 kg/m2 through 32.0 kg/m2, inclusive. - Participant must have Body weight ≥ 50 kg Exclusion Criteria: - Participant must not have current or recent GI disease - Participant with evidence of organ dysfunction or any clinically significant deviation, as determined by investigator, from normal in physical examination, vital signs, 12-lead ECG, or clinical laboratory determinations beyond what is consistent with the target population. - Participant with prior exposure to BMS-986278 and exposure of any investigational drug or placebo within 4 weeks of study intervention administration. - Other protocol-defined Inclusion/Exclusion criteria apply.
Recomendamos encarecidamente que se comunique con BMS para informar de los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica
